Navigation Links
Dan Broderick Joins Prolog Ventures as Partner
Date:9/12/2007

ST. LOUIS, Sept. 12 /PRNewswire/ -- Prolog Ventures, a venture capital firm specializing in life science investments, today announced that Dan Broderick has joined the firm as its fourth partner. Broderick brings more than 20 years of experience in early-stage investing, venture fund management, and technology commercialization.

Before coming to Prolog, Broderick was a managing director at Mason Wells in Milwaukee, WI, where he served on its board of directors and management committee and managed the Mason Wells Biomedical Fund -- the firm's first venture capital fund. Prior to this, he spent 18 years at the Mayo Clinic in Rochester, MN, where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.

"Dan's extensive industry experience and deal flow connections further strengthen Prolog's expertise in early-stage life science investing," said Ilya Nykin, managing director of Prolog. "He was involved in the creation, financing, and growth of more than 20 venture-backed companies in Prolog's core areas of focus, most of them early-stage. Having Dan on Prolog's team is a great boost to our mission of translating life science breakthroughs into successful ventures."

Broderick's professional accomplishments have prompted a number of prominent industry boards and advisory panels to seek his involvement. He is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.

"Not only is Dan an astute investor, but he is also a long-time colleague. We have an excellent track record of working together," sa
'/>"/>

SOURCE Prolog Ventures
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Visions: Broderick says Wisconsin should be in top third in venture capital
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These ... through the activities in the soil or in the ... the stress on reducing environmental pollution and on reducing ... and segments the bio fertilizers market with analysis and ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... 19 New long-term data from two pivotal, Phase ... arthritis (RA) receiving SIMPONI (TM) (golimumab) every four ... physical function response through one year. These new ... of Rheumatology (ACR) Annual Scientific Meeting. , "New data ...
... , QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna ... (the "Company"), a global biopharmaceutical company focused on ... has initiated activities intended to complete the clinical ... ghrelin agonist compound macimorelin (AEZS-130) which could be ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
Cached Biology Technology:New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 2New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 3New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 4New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 5New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 6New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 7New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 8New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 9New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 10AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... births resulting from in-vitro-fertilization (IVF), researchers at Yale School ... that estimates the reproductive potential of individual embryos, possibly ... higher success rate in women undergoing IVF. , Over ... the United States. In 2002, 3.1 embryos on average ...
... approach can kill bacteria in laboratory experiments and eliminate ... bacterial nutrient, according to research led by a University ... UW, the University of Iowa, and the University of ... of the Journal of Clinical Investigation. , Bacteria ...
... of light are providing insight into the complexities of the ... of how the human brain works. , Investigators at Duke ... engineered a strain of mice whose olfactory brain cells "fire" ... the cells a gene naturally present in green algae that ...
Cached Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: